Overview Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids Status: Terminated Trial end date: 2009-08-01 Target enrollment: Participant gender: Summary Safety and efficacy study of 25 and 50 mg doses of Proellex Phase: Phase 3 Details Lead Sponsor: Repros Therapeutics Inc.